Cargando…
Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study
The recent coronavirus outbreak has changed the world’s economy and health sectors due to the high mortality and transmission rates. Because the development of new effective vaccines or treatments against the virus can take time, an urgent need exists for the rapid development and design of new drug...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V. on behalf of King Saud University.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277949/ https://www.ncbi.nlm.nih.gov/pubmed/34909064 http://dx.doi.org/10.1016/j.arabjc.2021.103315 |
_version_ | 1783722162294620160 |
---|---|
author | Mahmud, Shafi Biswas, Suvro Kumar Paul, Gobindo Mita, Mohasana Akter Afrose, Shamima Robiul Hasan, Md. Sharmin Sultana Shimu, Mst. Uddin, Mohammad Abu Raihan Salah Uddin, Md. Zaman, Shahriar Kaderi Kibria, K.M. Arif Khan, Md. Bin Emran, Talha Abu Saleh, Md. |
author_facet | Mahmud, Shafi Biswas, Suvro Kumar Paul, Gobindo Mita, Mohasana Akter Afrose, Shamima Robiul Hasan, Md. Sharmin Sultana Shimu, Mst. Uddin, Mohammad Abu Raihan Salah Uddin, Md. Zaman, Shahriar Kaderi Kibria, K.M. Arif Khan, Md. Bin Emran, Talha Abu Saleh, Md. |
author_sort | Mahmud, Shafi |
collection | PubMed |
description | The recent coronavirus outbreak has changed the world’s economy and health sectors due to the high mortality and transmission rates. Because the development of new effective vaccines or treatments against the virus can take time, an urgent need exists for the rapid development and design of new drug candidates to combat this pathogen. Here, we obtained antiviral peptides obtained from the data repository of antimicrobial peptides (DRAMP) and screened their predicted tertiary structures for the ability to inhibit the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using multiple combinatorial docking programs, including PatchDock, FireDock, and ClusPro. The four best peptides, DRAMP00877, DRAMP02333, DRAMP02669, and DRAMP03804, had binding energies of −1125.3, −1084.5, −1005.2, and −924.2 Kcal/mol, respectively, as determined using ClusPro, and binding energies of −55.37, −50.96, −49.25, −54.81 Kcal/mol, respectively, as determined using FireDock, which were better binding energy values than observed for other peptide molecules. These peptides were found to bind with the active cavity of the SARS-CoV-2 main protease; at Glu166, Cys145, Asn142, Phe140, and Met165, in addition to the substrate-binding sites, Domain 2 and Domain 3, whereas fewer interactions were observed with Domain 1. The docking studies were further confirmed by a molecular dynamics simulation study, in which several descriptors, including the root-mean-square difference (RMSD), root-mean-square fluctuation (RMSF), solvent-accessible surface area (SASA), radius of gyration (Rg), and hydrogen bond formation, confirmed the stable nature of the peptide–main protease complexes. Toxicity and allergenicity studies confirmed the non-allergenic nature of the peptides. This present study suggests that these identified antiviral peptide molecules might inhibit the main protease of SARS-CoV-2, although further wet-lab experiments remain necessary to verify these findings. |
format | Online Article Text |
id | pubmed-8277949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier B.V. on behalf of King Saud University. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82779492021-07-14 Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study Mahmud, Shafi Biswas, Suvro Kumar Paul, Gobindo Mita, Mohasana Akter Afrose, Shamima Robiul Hasan, Md. Sharmin Sultana Shimu, Mst. Uddin, Mohammad Abu Raihan Salah Uddin, Md. Zaman, Shahriar Kaderi Kibria, K.M. Arif Khan, Md. Bin Emran, Talha Abu Saleh, Md. Arabian Journal of Chemistry Original Article The recent coronavirus outbreak has changed the world’s economy and health sectors due to the high mortality and transmission rates. Because the development of new effective vaccines or treatments against the virus can take time, an urgent need exists for the rapid development and design of new drug candidates to combat this pathogen. Here, we obtained antiviral peptides obtained from the data repository of antimicrobial peptides (DRAMP) and screened their predicted tertiary structures for the ability to inhibit the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using multiple combinatorial docking programs, including PatchDock, FireDock, and ClusPro. The four best peptides, DRAMP00877, DRAMP02333, DRAMP02669, and DRAMP03804, had binding energies of −1125.3, −1084.5, −1005.2, and −924.2 Kcal/mol, respectively, as determined using ClusPro, and binding energies of −55.37, −50.96, −49.25, −54.81 Kcal/mol, respectively, as determined using FireDock, which were better binding energy values than observed for other peptide molecules. These peptides were found to bind with the active cavity of the SARS-CoV-2 main protease; at Glu166, Cys145, Asn142, Phe140, and Met165, in addition to the substrate-binding sites, Domain 2 and Domain 3, whereas fewer interactions were observed with Domain 1. The docking studies were further confirmed by a molecular dynamics simulation study, in which several descriptors, including the root-mean-square difference (RMSD), root-mean-square fluctuation (RMSF), solvent-accessible surface area (SASA), radius of gyration (Rg), and hydrogen bond formation, confirmed the stable nature of the peptide–main protease complexes. Toxicity and allergenicity studies confirmed the non-allergenic nature of the peptides. This present study suggests that these identified antiviral peptide molecules might inhibit the main protease of SARS-CoV-2, although further wet-lab experiments remain necessary to verify these findings. The Author(s). Published by Elsevier B.V. on behalf of King Saud University. 2021-09 2021-07-14 /pmc/articles/PMC8277949/ /pubmed/34909064 http://dx.doi.org/10.1016/j.arabjc.2021.103315 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Mahmud, Shafi Biswas, Suvro Kumar Paul, Gobindo Mita, Mohasana Akter Afrose, Shamima Robiul Hasan, Md. Sharmin Sultana Shimu, Mst. Uddin, Mohammad Abu Raihan Salah Uddin, Md. Zaman, Shahriar Kaderi Kibria, K.M. Arif Khan, Md. Bin Emran, Talha Abu Saleh, Md. Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study |
title | Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study |
title_full | Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study |
title_fullStr | Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study |
title_full_unstemmed | Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study |
title_short | Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study |
title_sort | antiviral peptides against the main protease of sars-cov-2: a molecular docking and dynamics study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277949/ https://www.ncbi.nlm.nih.gov/pubmed/34909064 http://dx.doi.org/10.1016/j.arabjc.2021.103315 |
work_keys_str_mv | AT mahmudshafi antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT biswassuvro antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT kumarpaulgobindo antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT mitamohasanaakter antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT afroseshamima antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT robiulhasanmd antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT sharminsultanashimumst antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT uddinmohammadaburaihan antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT salahuddinmd antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT zamanshahriar antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT kaderikibriakm antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT arifkhanmd antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT binemrantalha antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy AT abusalehmd antiviralpeptidesagainstthemainproteaseofsarscov2amoleculardockinganddynamicsstudy |